Skip to content

Trial Summary

This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.



ACTRN/NCT /ethics:


Scientific title:

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Sponsor / Cooperative group:

Telix International Pty Ltd

Trial & Patient Characteristics

Cancer TypeBrain
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-04-02
Anticipated End Date2025-06-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorNimit Singhal
Recruitment StatusRecruiting